Literature DB >> 1685666

Anti-arrhythmic properties of the alpha-adrenoceptor blocking drug indoramin.

M A James1, J V Jones.   

Abstract

1. The anti-arrhythmic properties of the alpha-adrenoceptor blocking drug indoramin were compared with the effect of disopyramide and placebo in a randomised, single-blind, cross-over study. Two doses of indoramin were tested, 25 mg and 50 mg and the dose of disopyramide was 150 mg. All treatments were administered three times daily. 2. Forty patients with benign ventricular arrhythmia were studied. 3. Assessment was by 24 h ambulatory electrocardiography at entry and at the end of each 2 week treatment period. 4. Indoramin was found to have a significant anti-arrhythmic effect compared with placebo, but only at the higher dose tested. 5. The anti-arrhythmic effect was less than that achieved with disopyramide. 6. The mechanism for this anti-arrhythmic effect is unknown but these results suggest that alpha-adrenoceptor blockade may merit further attention as an anti-arrhythmic treatment.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1685666      PMCID: PMC1368534          DOI: 10.1111/j.1365-2125.1991.tb03915.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  22 in total

1.  The clinical pharmacology of indoramin.

Authors:  R G Shanks
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

2.  Current concepts in the treatment of cardiac arrhythmias.

Authors:  M Manz; W L Wagner; E Grube; B Lüderitz
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

3.  Experimental evidence for the antiarrhythmic action of indoramin.

Authors:  D W Harron
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

4.  Polymorphous ventricular tachycardia due to alpha-blockade.

Authors:  M A James; W Culling; J Vann Jones
Journal:  Int J Cardiol       Date:  1987-02       Impact factor: 4.164

5.  The rational basis and the clinical value of selective cardiac sympathetic denervation in the prevention of malignant arrhythmias.

Authors:  P J Schwartz; A Zaza
Journal:  Eur Heart J       Date:  1986-05       Impact factor: 29.983

6.  Can chronic antidysrhythmic treatment prevent sudden death?

Authors:  L M Friedman
Journal:  Eur Heart J       Date:  1984-09       Impact factor: 29.983

Review 7.  Mechanisms contributing to arrhythmias during ischaemia and infarction.

Authors:  J B Kramer; P B Corr
Journal:  Eur Heart J       Date:  1984-09       Impact factor: 29.983

8.  Antiarrhythmic and electrophysiological effects of alpha adrenoceptor blockade during myocardial ischaemia and reperfusion in isolated guinea-pig heart.

Authors:  W J Penny; W Culling; M J Lewis; D J Sheridan
Journal:  J Mol Cell Cardiol       Date:  1985-04       Impact factor: 5.000

9.  Arrhythmias in ischemic and nonischemic dilated cardiomyopathy: prediction of mortality by ambulatory electrocardiography.

Authors:  J Holmes; S H Kubo; R J Cody; P Kligfield
Journal:  Am J Cardiol       Date:  1985-01-01       Impact factor: 2.778

10.  Clinical cardiac electrophysiology of indoramin, a post-synaptic alpha blocker.

Authors:  G S Butrous; A J Camm
Journal:  Eur Heart J       Date:  1986-07       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.